Literature DB >> 22476808

Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer.

De-shen Wang1, Hui-yan Luo, Miao-zhen Qiu, Zhi-qiang Wang, Dong-sheng Zhang, Feng-hua Wang, Yu-hong Li, Rui-hua Xu.   

Abstract

The aim of the present study was to determine whether C-reactive protein (CRP)-based systemic inflammatory response scores (modified Glasgow prognostic score, mGPS; prognostic index, PI) have prognostic value superior to that of scores based on circulating white cells (neutrophil/lymphocyte ratio, NLR; platelet/lymphocyte ratio, PLR) or in combination with albumin (prognostic nutritional index, PNI) in patients with pancreatic cancer. The medical records of 177 patients with pancreatic adenocarcinoma were reviewed. Kaplan-Meier methodology and a multivariable Cox proportional hazards model were used to evaluate the potential prognostic factors. NLR > 5 was associated with higher white cell count, higher PLR, elevated CRP, hypoalbuminemia, increased mGPS, PI and PNI, poorer performance status (PS), greater weight loss and poorer tumor differentiation. On multivariate analysis, only NLR (HR, 2.537; 95 % CI, 1.313-4.902; p = 0.006), PS, tumor-node-metastasis (TNM) staging, type of surgery and palliative chemotherapy were associated independently with survival, whereas PLR, mGPS, PI and PNI were not. NLR > 5 predicted poorer overall survival (OS) compared with NLR ≤ 5 (median OS, 4.133 and 9.300, respectively; p = 0.006). On the subgroup analysis, the median OS of patients with NLR > 5 was 5.767 months, whereas patients with NLR ≤ 5 who had received palliative chemotherapy had a median OS of 10.200 months (p < 0.001). Our study demonstrates that elevated NLR is superior to the mGPS, PI, PLR and PNI for prognostication in patients with pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476808     DOI: 10.1007/s12032-012-0226-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  38 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma.

Authors:  G Garcea; N Ladwa; C P Neal; M S Metcalfe; A R Dennison; D P Berry
Journal:  World J Surg       Date:  2011-04       Impact factor: 3.352

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 5.  Nonsteroidal anti-inflammatory drugs and cancer prevention.

Authors:  J A Baron; R S Sandler
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

6.  The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer.

Authors:  G Kasymjanova; N MacDonald; J S Agulnik; V Cohen; C Pepe; H Kreisman; R Sharma; D Small
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

7.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

8.  Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer.

Authors:  Paul Glen; Nigel B Jamieson; Donald C McMillan; Ross Carter; Clem W Imrie; Colin J McKay
Journal:  Pancreatology       Date:  2006-07-13       Impact factor: 3.996

9.  Malignant tumors in the head of the pancreas and the periampullary region. Diagnostic and prognostic aspects.

Authors:  F Griffanti-Bartoli; G B Arnone; P Ceppa; G Ravera; S Carrabetta; D Civalleri
Journal:  Anticancer Res       Date:  1994 Mar-Apr       Impact factor: 2.480

Review 10.  A systematic review of the association between circulating concentrations of C reactive protein and cancer.

Authors:  Katriina Heikkilä; Shah Ebrahim; Debbie A Lawlor
Journal:  J Epidemiol Community Health       Date:  2007-09       Impact factor: 3.710

View more
  101 in total

1.  Response.

Authors:  David Goldstein; Daniel Von Hoff
Journal:  J Natl Cancer Inst       Date:  2015-08-06       Impact factor: 13.506

2.  The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients.

Authors:  Shaodong Hong; Ting Zhou; Wenfeng Fang; Cong Xue; Zhihuang Hu; Tao Qin; Yanna Tang; Yue Chen; Yuxiang Ma; Yunpeng Yang; Xue Hou; Yan Huang; Hongyun Zhao; Yuanyuan Zhao; Li Zhang
Journal:  Tumour Biol       Date:  2014-12-20

3.  High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer.

Authors:  Christos Perisanidis; Gabriela Kornek; Paul W Pöschl; Daniel Holzinger; Katharina Pirklbauer; Christian Schopper; Rolf Ewers
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

4.  Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome.

Authors:  Traian Dumitrascu; Dragos Chirita; Mihnea Ionescu; Irinel Popescu
Journal:  J Gastrointest Surg       Date:  2013-01-15       Impact factor: 3.452

5.  Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer.

Authors:  Yuan Gao; Wen-Jie Wang; Qiaoming Zhi; Meng Shen; Min Jiang; Xiaojie Bian; Fei-Ran Gong; Chong Zhou; Lian Lian; Meng-Yao Wu; Jun Feng; Min Tao; Wei Li
Journal:  Oncotarget       Date:  2017-09-27

Review 6.  Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma.

Authors:  Chung-Tzu Hsueh; Julie H Selim; James Y Tsai; Chung-Tsen Hsueh
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

7.  Prognostic Scoring System for Patients Who Present with a Gastric Outlet Obstruction Caused by Advanced Pancreatic Adenocarcinoma.

Authors:  Teiichi Sugiura; Yukiyasu Okamura; Takaaki Ito; Yusuke Yamamoto; Ryo Ashida; Yukio Yoshida; Masaki Tanaka; Katsuhiko Uesaka
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

8.  Preoperative Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio Cannot Predict Lymph Node Metastasis and Prognosis in Patients with Early Gastric Cancer: a Single Institution Investigation in China.

Authors:  Guang-Sheng Zhu; Shao-Bo Tian; Hui Wang; Mao-Guang Ma; Ya Liu; Han-Song Du; Yue-Ping Long
Journal:  Curr Med Sci       Date:  2018-03-15

9.  FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.

Authors:  E Bonnet; C Mastier; A Lardy-Cléaud; P Rochefort; M Sarabi; P Guibert; A Cattey-Javouhey; F Desseigne; C de La Fouchardière
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

10.  Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma.

Authors:  Xing Li; Zhan-Hong Chen; Xiao-Kun Ma; Jie Chen; Dong-Hao Wu; Qu Lin; Min Dong; Li Wei; Tian-Tian Wang; Dan-Yun Ruan; Ze-Xiao Lin; Yan-Fang Xing; Yun Deng; Xiang-Yuan Wu; Jin-Yun Wen
Journal:  Tumour Biol       Date:  2014-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.